ANALYST: BLOCKBUSTER POTENTIAL
Investors eyeing Aerie Pharma's Roclatan after positive phase IIb glaucoma data
By Karen Pihl-Carey
Wednesday, June 25, 2014
Reducing intraocular pressure (IOP) in a phase IIb trial and providing new hope for glaucoma patients, Aerie Pharmaceuticals Inc.'s quadruple-acting combination drug Roclatan nailed its primary endpoint by showing statistically significant superiority over each of its components.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.